302 related articles for article (PubMed ID: 8768870)
1. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone.
Ellis KJ; Lee PD; Pivarnik JM; Bukar JG; Gesundheit N
J Clin Endocrinol Metab; 1996 Aug; 81(8):3033-8. PubMed ID: 8768870
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection.
Lee PD; Pivarnik JM; Bukar JG; Muurahainen N; Berry PS; Skolnik PR; Nerad JL; Kudsk KA; Jackson L; Ellis KJ; Gesundheit N
J Clin Endocrinol Metab; 1996 Aug; 81(8):2968-75. PubMed ID: 8768860
[TBL] [Abstract][Full Text] [Related]
3. Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial.
Sevette A; Smith RC; Aslani A; Kee AJ; Hansen R; Barratt SM; Baxter RC
Clin Nutr; 2005 Dec; 24(6):943-55. PubMed ID: 16083996
[TBL] [Abstract][Full Text] [Related]
4. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
[TBL] [Abstract][Full Text] [Related]
5. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
6. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
[TBL] [Abstract][Full Text] [Related]
7. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.
Grinspoon S; Corcoran C; Lee K; Burrows B; Hubbard J; Katznelson L; Walsh M; Guccione A; Cannan J; Heller H; Basgoz N; Klibanski A
J Clin Endocrinol Metab; 1996 Nov; 81(11):4051-8. PubMed ID: 8923860
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects.
Clemmons DR; Snyder DK; Williams R; Underwood LE
J Clin Endocrinol Metab; 1987 May; 64(5):878-83. PubMed ID: 3558728
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
10. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome.
Lieberman SA; Butterfield GE; Harrison D; Hoffman AR
J Clin Endocrinol Metab; 1994 Feb; 78(2):404-10. PubMed ID: 7508949
[TBL] [Abstract][Full Text] [Related]
11. Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults.
Ehrnborg C; Ellegård L; Bosaeus I; Bengtsson BA; Rosén T
Clin Endocrinol (Oxf); 2005 Apr; 62(4):449-57. PubMed ID: 15807876
[TBL] [Abstract][Full Text] [Related]
12. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans.
Snyder DK; Clemmons DR; Underwood LE
J Clin Endocrinol Metab; 1989 Oct; 69(4):745-52. PubMed ID: 2778033
[TBL] [Abstract][Full Text] [Related]
13. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, placebo-controlled study.
Hansen TB; Vahl N; Jørgensen JO; Christiansen JS; Hagen C
Clin Endocrinol (Oxf); 1995 Dec; 43(6):689-96. PubMed ID: 8736270
[TBL] [Abstract][Full Text] [Related]
14. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition.
Snyder DK; Clemmons DR; Underwood LE
J Clin Endocrinol Metab; 1988 Jul; 67(1):54-61. PubMed ID: 3379136
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
16. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
[TBL] [Abstract][Full Text] [Related]
17. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men.
de Boer H; Blok GJ; Voerman B; Derriks P; van der Veen E
Int J Obes Relat Metab Disord; 1996 Jun; 20(6):580-7. PubMed ID: 8782736
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
19. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women.
Thompson JL; Butterfield GE; Gylfadottir UK; Yesavage J; Marcus R; Hintz RL; Pearman A; Hoffman AR
J Clin Endocrinol Metab; 1998 May; 83(5):1477-84. PubMed ID: 9589642
[TBL] [Abstract][Full Text] [Related]
20. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
